All News

RheumNow Podcast square

PsA All the Way – Unmet Needs

Jack Cush, MD

Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss key advances and modern disease management. We're featuring guest bloggers, hosting Tuesday Night Rheumatology, posting slides and videos, and much more dedicated to PsA.

Read Article
Psoriasis Severe legs sara

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

Jack Cush, MD

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Read Article
PsA.Hands_.jpg

Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis

Jack Cush, MD

An interesting study in Lancet Rheumatology shows that psoriatic arthritis patients not responding to methotrexate alone can respond after adding or escalating adalimumab (ADA) on top of methotrexate (MTX) to reach minimal disease activity (MDA) response. 

Read Article
Danish study of opioids in psoriasis (n 4016), PsA (847) & controls (3490). Opioid Use within 12 months seen in 9% general population, 14.2% psoriasis without PsA, & 22.7% concomitant PsA pts. Joint pain incr analgesic use (OR 3.72) #PsAlways https://t.co/WKrA8sChyN https://t.co/9FLq4mKz7V

Links:

Dr. John Cush RheumNow ( View Tweet)
Differences in Biologic Persistence in PsO and PsA Administrative claims analysis of biologic use in PsO and PsA in French health insurance databases shows that despite widespread biologic use, overall drug persistence was low for PsO and PsA biologics. https://t.co/PtrXu9xyFa https://t.co/RWciF4DqXj

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis https://t.co/q0uIjLrT3G https://t.co/ehgEUSrbPg

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. J Merola discusses the bridges and gaps in PsO/PsA care here in the US. #RNL2022 @RheumNow https://t.co/hIdtRzeUC3
Dr. Rachel Tate uptoTate ( View Tweet)
Network meta-analysis reviewing PsO biologic treatments and QoL reviewed by Dr. K. Gordon at #RNL2022 @RheumNow https://t.co/BV8s1LJ7VX
Dr. Rachel Tate uptoTate ( View Tweet)
"Going to a dermatologist is like going to a bagel shop, you're gonna get a 'smear'" - Dr. K Gordon #RNL2022 on use of topical corticosteroids as a tool that we should not forget for pts w/#psoriasis https://t.co/vCjMyKe5AE
TheDaoIndex KDAO2011 ( View Tweet)
"Remember bony growth is a feature of the PsA joint and one potential way in which IL17s may target the disease." Dr. B. Kirkham discusses potential synergistic activity of IL17A and TNFi in the SpA joint. #RNL2022 @RheumNow https://t.co/L9uZqoen2w
Dr. Rachel Tate uptoTate ( View Tweet)
"Instead of using the term moderate to severe PsO, I use systemic treatment eligible PsO," when thinking about medications for PsO patients. Dr. B. Strober. #RNL2022 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Do you use Otezla with biologics in PsA? #RNL2022 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

IL-17i - Good Long term safety profile and low malignancy risk Best efficacy for nail psoriasis @RheumNow #RNL2022 https://t.co/8T7wAGJChF
Robert B Chao, MD doctorRBC ( View Tweet)
"The most important thing to consider is what is the risk of PsO on the overall health (of the patient.)" BSA > 10% showed increase all cause mortality rates in IHOPE study. Dr. K. Gordon discusses PsO treatment complexity and importance at #RNL2022 @RheumNow https://t.co/ouHPbLmlqD
Dr. Rachel Tate uptoTate ( View Tweet)
Have you seen the MTX data regarding PsO? Dr. Gordon reviews the METOP data. My take homes: MTX has moderate efficacy and takes a long time! #RNL2022 @RheumNow https://t.co/B28onPUKn8
Dr. Rachel Tate uptoTate ( View Tweet)
Excellent charts presented by Dr. Kenneth Gordon on the PASI response and QoL response amongst different PsO therapies @RheumNow #RNL2022 https://t.co/e3gqcPzk79
Robert B Chao, MD doctorRBC ( View Tweet)
How to treat #psoriasis #PsO Indivualize for pt. OK to try more than one drug within a class if initial fails or isn’t tolerated. Common I think to have 2ndary loss of response even with dose escalation. Skin is sneaky immunologically! #RNL2022 @RheumNow https://t.co/pFPNCVLSvk
Janet Pope Janetbirdope ( View Tweet)
#ClinicalPearl Fun fact According to Dr Strober IL17i have BEST effects on nail involvement in #psoriasis. I didn’t know. often need ⬆️dose over time #RNL2022 @RheumNow https://t.co/Y9U9c4M03j
Janet Pope Janetbirdope ( View Tweet)
Current treatment paradigm for PsO @RheumNow #RNL2022 https://t.co/yDc3Pk0RjI
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2022 Psoriatic Disease for Rheumatologists with Drs. Gordon and Merida. https://t.co/PEj0dI7ucH
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×